NCT06941844Phase 3Active not recruiting

A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)

Study sponsor: Definium Therapeutics US, Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-05-20Actual
Enrollment · participants149Actual
Source updated2026-08-28Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Nov 2026. After: 20 May 2026.

Check registry source

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 140 participants (planned). After: 149 participants (actual).

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source